Joseph DePalo1, Xiaoyu Chai2, Stephanie J Lee2, Corey S Cutler3, Nathaniel Treister4. 1. Harvard School of Dental Medicine, 188 Longwood Avenue, Boston, MA 02115, USA. 2. Clinical Research Division, Fred Hutchinson Cancer Research Center, 1100 Fairview Avenue North, Seattle, WA 98109, USA. 3. Hematologic Malignancies, Dana-Farber Cancer Institute, 450 Brookline Avenue, Boston, MA 02215, USA. 4. Brigham and Women's Hospital, Division of Oral Medicine and Dentistry, 1620 Tremont Street, Suite BC-3-028, Boston, MA 02120, USA. Electronic address: ntreister@partners.org.
Abstract
OBJECTIVE: Chronic GVHD (cGVHD) is a frequent complication of allogeneic hematopoietic stem cell transplantation (HSCT) and affects multiple organ systems, with the oral cavity being one of the most frequently affected sites. Patients with cGVHD experience reduced quality of life (QOL), yet the specific impact of oral cGVHD on QOL is poorly understood. The objective of this study was to characterize the impact of oral cGVHD on global measures of QOL. MATERIALS AND METHODS: QOL data were collected using the FACT-BMT and SF-36 instruments for 569 patients enrolled in the Chronic GVHD Consortium, with a total of 1915 follow-up visits. At study enrollment, patients were categorized as isolated oral cGVHD (n=22), oral and concomitant extra-oral cGVHD (n=420), and only extra-oral cGVHD (n=127). Utilizing all longitudinal data, QOL scores were compared using a multivariable linear model controlling for demographic, transplant, and cGVHD characteristics. RESULTS: Patients with isolated oral cGVHD reported better physical well-being (P=0.009), BMT well-being (P=0.01), and decreased bodily pain (P=0.01) compared to patients with oral and concomitant extra-oral cGVHD, but the differences in scores did not reach the defined threshold for clinical significance (6 points for FACT-BMT domains and 5 points for SF-36 domains). CONCLUSIONS: Global QOL scores are similar in patients with isolated oral cGVHD and patients with oral and concomitant extra-oral cGVHD.
OBJECTIVE: Chronic GVHD (cGVHD) is a frequent complication of allogeneic hematopoietic stem cell transplantation (HSCT) and affects multiple organ systems, with the oral cavity being one of the most frequently affected sites. Patients with cGVHD experience reduced quality of life (QOL), yet the specific impact of oral cGVHD on QOL is poorly understood. The objective of this study was to characterize the impact of oral cGVHD on global measures of QOL. MATERIALS AND METHODS: QOL data were collected using the FACT-BMT and SF-36 instruments for 569 patients enrolled in the Chronic GVHD Consortium, with a total of 1915 follow-up visits. At study enrollment, patients were categorized as isolated oral cGVHD (n=22), oral and concomitant extra-oral cGVHD (n=420), and only extra-oral cGVHD (n=127). Utilizing all longitudinal data, QOL scores were compared using a multivariable linear model controlling for demographic, transplant, and cGVHD characteristics. RESULTS:Patients with isolated oral cGVHD reported better physical well-being (P=0.009), BMT well-being (P=0.01), and decreased bodily pain (P=0.01) compared to patients with oral and concomitant extra-oral cGVHD, but the differences in scores did not reach the defined threshold for clinical significance (6 points for FACT-BMT domains and 5 points for SF-36 domains). CONCLUSIONS: Global QOL scores are similar in patients with isolated oral cGVHD and patients with oral and concomitant extra-oral cGVHD.
Authors: C W Bassim; H Fassil; J W Mays; D Edwards; K Baird; S M Steinberg; K M Williams; E W Cowen; S A Mitchell; K Cole; T Taylor; D Avila; D Zhang; D Pulanic; L Grkovic; D Fowler; R E Gress; S Z Pavletic Journal: Bone Marrow Transplant Date: 2013-09-02 Impact factor: 5.483
Authors: C W Bassim; H Fassil; M Dobbin; S M Steinberg; K Baird; K Cole; G Joe; L E Comis; S A Mitchell; L Grkovic; D Edwards; J W Mays; E W Cowen; D Pulanic; K M Williams; R E Gress; S Z Pavletic Journal: Bone Marrow Transplant Date: 2014-07-14 Impact factor: 5.483
Authors: T Daikeler; M Mauramo; A Rovó; M Stern; J Halter; A Buser; A Tyndall; P Häusermann; A Gratwohl; A Tichelli; M T Brennan; T Waltimo Journal: Bone Marrow Transplant Date: 2013-01-07 Impact factor: 5.483
Authors: Joseph Pidala; Brenda F Kurland; Xiaoyu Chai; Georgia Vogelsang; Daniel J Weisdorf; Steven Pavletic; Corey Cutler; Navneet Majhail; Stephanie J Lee Journal: Haematologica Date: 2011-06-17 Impact factor: 9.941
Authors: Mary E D Flowers; Yoshihiro Inamoto; Paul A Carpenter; Stephanie J Lee; Hans-Peter Kiem; Effie W Petersdorf; Shalini E Pereira; Richard A Nash; Marco Mielcarek; Matthew L Fero; Edus H Warren; Jean E Sanders; Rainer F Storb; Frederick R Appelbaum; Barry E Storer; Paul J Martin Journal: Blood Date: 2011-01-24 Impact factor: 22.113
Authors: Carol W Bassim; Kiran S Ambatipudi; Jacqueline W Mays; Dean A Edwards; Stephan Swatkoski; Helen Fassil; Kristin Baird; Marjan Gucek; James E Melvin; Steven Z Pavletic Journal: J Clin Immunol Date: 2012-07-18 Impact factor: 8.317
Authors: Hussein Soudy; Irfan Maghfoor; Tusneem Ahmed M Elhassan; Eman Abdullah; Shahzad M Rauf; Ahmed Al Zahrani; Saad Akhtar Journal: Health Qual Life Outcomes Date: 2018-03-12 Impact factor: 3.186
Authors: Angela da Costa Barcellos Marques; Ana Paula Szczepanik; Celina Angélica Mattos Machado; Pâmella Naiana Dias Santos; Paulo Ricardo Bittencourt Guimarães; Luciana Puchalski Kalinke Journal: Rev Lat Am Enfermagem Date: 2018-10-25
Authors: Juliette Stolze; Marlou Boor; Mette D Hazenberg; Henk S Brand; Judith E Raber-Durlacher; Alexa M G A Laheij Journal: Support Care Cancer Date: 2021-04-21 Impact factor: 3.603